Skip to content

Randomized, double-blind, placebo-controlled parallel-group comparative study to evaluate the efficacy of probiotics on reducing body fat

Randomized, double-blind, placebo-controlled parallel-group comparative study to evaluate the efficacy of probiotics on reducing body fat - Clinical study to evaluate the efficacy of probiotics on reducing body fat

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000047852
Enrollment
100
Registered
2022-05-27
Start date
2022-05-30
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Oral ingestion of the test food for 16 weeks Oral ingestion of the placebo food for 16 weeks

Sponsors

KSO Corporation
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Subjects aged more than 20 years, less than 65 years 2) Subjects of BMI between 23 and 30

Exclusion criteria

Exclusion criteria: 1) Subjects who have history of serious disease 2) Subjects who regularly undertake medications that affect obesity, hyperlipidemia or lipid metabolism 3) Subjects who cannot stop taking health foods or supplements that affect obesity, hyperlipidemia or lipid metabolism 4) Heavy smokers 5) Subjects who have excessive alcoholic drinks 6) Subjects with serious medication allergy or food allergy 7) Subjects who have metal in the CT scan measurement site due to surgery, etc. 8) Subjects with cardiac pacemakers or implantable cardioverter defibrillators. 9) Subject who is pregnant or under lactation, or who is expected to be pregnant during the study 10) Subjects who are currently participating, or intend to participate during this study period, in other trials involving the testing of other foods or the use of drugs or the application of cosmetics and drugs 11) Subjects who are considered to be inappropriate for this study by the principal investigator

Design outcomes

Primary

MeasureTime frame
Body composition(abdominal fat, body fat)

Secondary

MeasureTime frame
Anthropometry, Serum lipids, Blood glucose-related variables, Liver function, Inflammatory marker

Countries

Japan

Contacts

Public ContactEiji Yoshikawa

KSO Corporation Sales department

yoshikawa@kso.co.jp03-3452-7733

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026